EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial

Hiroyuki Tsutsui, Hiroyuki Sakamaki, Shin-Ichi Momomura, Yasushi Sakata, Yutaro Kotobuki, Stephan Linden, Odette S Reifsnider, Pal Rakonczai, Matthew Stargardter, Tatsunori Murata, Tetsuaki Hirase, Daisuke Nitta

Journal of Cardiology · 2023

DOI: 10.1016/j.jjcc.2023.02.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiology, 2023. Verfasst von Hiroyuki Tsutsui und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan. Electronic address: tsutsui.hiroyuki.691@m.kyu…. Hauptthemen laut MEDLINE: Heart Failure, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Several studies have reported the cost-effectiveness of sodium-glucose co-transporter 2 inhibitors in heart failure patients; however, their economic implications have not been sufficiently elucidated in Japan. METHODS: A Markov cohort model was developed to evaluate the cost-effectiveness of empagliflozin plus standard of care (SoC) vs. SoC for patients with heart failure with reduced ejection fraction (HFrEF) in Japan. Model inputs, including risk of clinical events, costs, and utilities based on Kansas City Cardiomyopathy Questionnaire Clinical Summary Scores were derived from EMPEROR-Reduced trial data, published literature, and a claims database. RESULTS: The model predicted lower lifetime hospitalizations for heart failure (HHFs) and additional quality-adjusted life-years (QALYs; 0.21) for empagliflozin plus SoC vs. SoC in the overall population. Increased costs of ¥100,495/patient ($772/patient), primarily driven by higher drug costs of ¥239,558/patient ($1,840/patient), were largely offset by reduced HHF management costs of -¥166,160/patient (-$1,276/patient), yielding an incremental cost-effectiveness ratio (ICER) of ¥469,672/QALY ($3,608/QALY). Results were consistent among subgroups and sensitivity analyses. In probabilistic sensitivity analysis, 82.5 % of runs were below the Japanese ICER reference value of ¥5,000,000/QALY ($38,408/QALY). CONCLUSIONS: Empagliflozin was demonstrated to be cost-effective for HFrEF patients in Japan based on the EMPEROR-Reduced trial data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureSodium-Glucose Transporter 2 InhibitorsHumansCost-Effectiveness AnalysisJapanStroke VolumeCost-Benefit AnalysisBenzhydryl CompoundsQuality-Adjusted Life YearsGlucosides

Stichwörter der Autor:innen

Cost-effectiveness analysisEMPEROR-reducedEmpagliflozinHeart failure with reduced ejection fraction

Substanzen

Benzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsempagliflozinGlucosides

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan. Electronic address: tsutsui.hiroyuki.691@m.kyushu-u.ac.jp.
  • Kanagawa University of Human Services, School of Health Innovation, Kanagawa, Japan.
  • Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
  • Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Medicine Division, Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan. Electronic address: yutaro.kotobuki@boehringer-ingelheim.com.
  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.

Zitieren

APA

Tsutsui, H., Sakamaki, H., Momomura, S. I., Sakata, Y., Kotobuki, Y., Linden, S., Reifsnider, O. S., Rakonczai, P., Stargardter, M., Murata, T., Hirase, T., & Nitta, D. (2023). Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial. Journal of Cardiology. https://doi.org/10.1016/j.jjcc.2023.02.007

Vancouver

Tsutsui H, Sakamaki H, Momomura SI, Sakata Y, Kotobuki Y, Linden S, et al. Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial. Journal of Cardiology. 2023. doi:10.1016/j.jjcc.2023.02.007

BibTeX
@article{Tsutsui2023,
  author = {Tsutsui, Hiroyuki and Sakamaki, Hiroyuki and Momomura, Shin-Ichi and Sakata, Yasushi and Kotobuki, Yutaro and Linden, Stephan and Reifsnider, Odette S and Rakonczai, Pal and Stargardter, Matthew and Murata, Tatsunori and Hirase, Tetsuaki and Nitta, Daisuke},
  title = {Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial},
  journal = {Journal of Cardiology},
  year = {2023},
  doi = {10.1016/j.jjcc.2023.02.007}
}
Kostenlos starten →